Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALKBH1 | Q13686 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL322839 | 0.78 | LMNA (1.00) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL29425707 | 0.78 | LMNA (1.00) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL14822077 | 0.76 | LMNA (0.56) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL3380687 | 0.76 | LMNA (0.56) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL1819465 | 0.76 | LMNA (0.49) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL22573474 | 0.74 | ADORA2A (0.50) | LMNAADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL1644320 | 0.74 | LMNA (0.55) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL32810 | 0.74 | KDM4E (0.46) | LMNAKMT2AKDM4EALDH1A1ADORA3 | |
| SCHEMBL18218832 | 0.73 | ALDH1A1 (0.44) | LMNAKMT2AKDM4EALDH1A1RXFP1 | |
| SCHEMBL2898655 | 0.73 | ADORA2A (0.47) | LMNAKMT2AKDM4EALDH1A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| CN-103958473-B | Amide compound, composition and application thereof | ADVINUS THERAPEUTICS LTD. (IN) | 2016-11-30 | — | — | CN | disclosed |
| US-20150065464-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| EP-2758375-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-07-30 | — | — | EP | disclosed |
| CN-103958473-A | Amide compound, composition and application thereof | ADVINUS THERAPEUTICS LTD | 2014-07-30 | — | — | CN | disclosed |
| CN-101538246-B | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC | 2014-07-16 | — | — | CN | disclosed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| CN-101538246-A | Pyrimidine amide compounds as pgds inhibitors | AVENTIS PHARMA INC | 2009-09-23 | — | — | CN | disclosed |
| CN-101282943-A | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC (US) | 2008-10-08 | — | — | CN | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1937652-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | LMNA 3675/4885KMT2A 3407/4885POLB 385/4885 |
| US-20150065464-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | FAAH, FAAH2, TPH1 | LMNA 1397/4885KMT2A 659/4885POLB 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.